Rocket One (RKTO) Cash from Financing Activities (2018 - 2026)
Rocket One's (RKTO) quarterly Cash from Financing Activities came in at $6.8 million in Q2 2026, up 10209.42% year-over-year from N/an in Q2 2025, and up 871.46% quarter-over-quarter from $701484.0 in Q1 2026.
Analysis
Rocket One (RKTO) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Rocket One has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $6.8 million for Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 10209.42% year-over-year to $6.8 million; the TTM figure through Jun 2026 stood at $9.7 million (up 18.31% YoY), while the FY2025 annual figure was $9.3 million, up 96.3% from the prior year.
- Cash from Financing Activities came in at $6.8 million for Q2 2026 at Rocket One, up from $701484.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $8.9 million in Q1 2023 to a low of $50990.0 in Q4 2022.
- Average Cash from Financing Activities over 5 years is $2.9 million, with a median of $1.3 million recorded in 2024.
- The largest YoY upside for Cash from Financing Activities was 10209.42% in 2026 against a maximum downside of 90.07% in 2026.
- Over 5 years, Cash from Financing Activities stood at $50990.0 in 2022, then surged by 4618.5% to $2.4 million in 2023, then sank by 55.91% to $1.1 million in 2024, then plunged by 48.14% to $550138.0 in 2025, then jumped by 1138.71% to $6.8 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $6.8 million in Q2 2026, $701484.0 in Q1 2026, and $550138.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Rocket One | 13.86 Mn | 5.97 Mn | - | 6.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.81 Mn |
| Mar 31, 2026 | 701,484.00 |
| Dec 31, 2025 | 550,138.00 |
| Sep 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | 66,101.00 |
| Mar 31, 2025 | 7.07 Mn |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2023 | 2.41 Mn |
| Mar 31, 2023 | 8.91 Mn |
| Dec 31, 2022 | 50,990.00 |
| Sep 30, 2021 | -100,000.00 |
| Jun 30, 2021 | -136,732.00 |
| Mar 31, 2021 | 18.43 Mn |
| Jun 30, 2020 | 4.49 Mn |
| Mar 31, 2020 | 4.23 Mn |
| Sep 30, 2019 | 1.61 Mn |
| Jun 30, 2019 | -17,169.00 |
| Mar 31, 2019 | 5.86 Mn |
| Sep 30, 2018 | -31,514.00 |
| Mar 31, 2018 | 1.19 Mn |